Applied DNA Sciences Reports

Applied DNA Sciences Reports

Fourth Consecutive Quarter of Record Revenues

Quarterly Revenue Up 76% Sequentially;

Annual Revenue Three-fold Prior Year;

Reports First-Time Positive Adjusted Quarterly EBITDA

Company To Hold Conference Call and Webcast

Tuesday, December 15, 2015 at 8:30 AM EST.

STONY BROOK, N.Y. December14, 2015.Applied

DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA") (Twitter: @APDN), a provider of DNA-based supply-chain, anti-counterfeiting

and anti-theft technology, product genotyping and product authentication solutions, announced financial results for the full fiscal

year and quarter ended September 30, 2015.

Dr. James A. Hayward, President and

Chief Executive Officer, stated, "We are proud to report our fourth consecutive quarter of record revenues and, for the first

time in the company's history, positive adjusted quarterly EBITDA. Our performance reflects the continued deployment of our

botanical DNA-based solutions to secure global supply chains, coupled with the continued disciplined management of operating expenses.

In particular, fourth quarter revenues reflect the provision of SigNature DNA adequate to mark an increment of

70 million pounds of Pima and Upland cotton, a quantity indicative of a commercial-scale deployment, as well as revenues from two

non-recurring government contracts. We believe that our penetration of the textile industry is very much in its infancy."

Fourth Quarter Financial Highlights:

Dr. Hayward continued, "Fiscal

2015 signaled Applied DNA Sciences' transition from a development-stage company to a commercial operating company and, by

every measure- operationally, financially, strategically -the year was a tremendous success. Additional relationships

within our government vertical, the supply of bulk DNA and new partnerships in the textile industry served as catalysts for substantial

revenue growth over the prior year. Reflective of our improved financial performance, we uplisted to the NASDAQ Stock Market to

raise our visibility to the investment community and accessed the capital markets to further fuel our growth. Our efforts have

culminated in an increase in revenue to three-fold the prior year, and the recent acquisition of Vandalia assets that not only

provides us entr e to new markets for our solutions, but also gives us additional capability to scale our solutions to meet

the requirements of current and future markets."

Financial Highlights for Fiscal 2015:

Dr. Hayward concluded, "Fiscal

2016 presents an opportunity for continued strong growth as the maturation of existing pilot projects become new drivers of revenue

and as we further expand our penetration of our existing industry verticals. Our success in validating cotton supply chains, which

are dispersed over large geographies and notoriously complex, sets the precedent for our deployment in other verticals from plastics

to pharmaceutics. Our cotton initiative helped the company mature from providing a DNA product to evolving procedures and systems

that complete the supply-chain ecosystem. We also expect to begin deployment of our On-Site DNA Authentication program for cotton,

which should serve to mitigate the impact of cotton's seasonality on our business.Subsequent to the close of the year, we

undertook a capital raise that further strengthened our balance sheet,giving us the flexibility to pursue a broader range of growth

opportunities. Given these and other initiatives, we expect further revenue growth in FY 2016.With an unmatched portfolio of DNAintellectual

property and the ability to produce DNA at scale, growing adoption of our solutions by markets with substantial dollar-value opportunities

and the financial resources with which to pursue them, we believe Applied DNA Sciences is excellently positioned to succeed."

Fiscal Fourth Quarter 2015 Conference Call Information

The Company will hold a conference call and webcast to discuss

its fiscal fourth quarter and year-end 2015 results on Tuesday, December 15, 2015 at 8:30 AM EST.To participate on the conference

call, please follow the instructions below. While every attempt will be made to answer investors' questions on the Q&A

portion of the call, due to the large number of expected participants, not all questions may be answered.

Reserve your conference call seat now at: http://dpregister.com/10077197.

Conference call dial-in information will be provided upon completion of the registration process.

Live webcast: http://services.choruscall.com/links/apdn151215

Replay (available 1 hour following the conclusion of the

For those investors unable to attend the live call, a copy of

the presentation is expected to be posted by end of business on December 15, 2015 and available under the "Investor Information"

tab of the company's web site.

Information about Non-GAAP Financial Measures

As used herein, "GAAP" refers to accounting principles

generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and

presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined

in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a

numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes

or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented

in accordance with GAAP.The presentation of this non-GAAP financial information is not intended to be considered in isolation or

as a substitute for, or superior to, the financial information prepared is presented in accordance with GAAP. We use this non-GAAP

financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons

of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures

provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not

be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow

for greater transparency with respect to key metrics used by management in its financial and operational decision making.

"EBITDA"- is defined as earnings (loss) before interest

expense, income tax expense and depreciation and amortization expense.

"Adjusted EBITDA"- is defined as EBITDA adjusted

to exclude (i) change in fair value of warrant liability, (ii) the loss on conversion of promissory notes, (iii) stock-based compensation

and (iv) other non-cash expenses.

About Applied DNA Sciences

We make life real and safe by providing botanical-DNA based

security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual

property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature DNA describes

the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the

core of a family of uncopyable products such as DNAnet , our anti-theft product, SigNature T, targeted toward textiles,

and digitalDNA , providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute

perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Applied DNA Sciences common stock is listed on NASDAQ under

the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements

The statements made by APDN in this press release may

be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking

statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve

a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from

those projected due to our short operating history, limited financial resources, limited market acceptance, market competition

and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form

10-K filed on December 14, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly

any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence

of unanticipated events, unless otherwise required by law.

investor contact:Debbie

Bailey, 631-240-8817, debbie.bailey@adnas.com

Sanjay M. Hurry, 212-838-3777, LHA, shurry@lhai.com

Forman, Dian Griesel Int'l., 212-825-3210,sforman@dgicomm.com

Financial Tables Follow

APPLIED DNA SCIENCES,

CONSOLIDATED BALANCE SHEETS

APPLIED DNA SCIENCES, INC.